Showing papers by "Adam Brufsky published in 2007"
TL;DR: Results of the primary end point of the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in postmenopausal women receiving adjuvant letrozole for early-stage breast cancer.
Abstract: Purpose Treatment with aromatase inhibitors decreases bone mineral density (BMD) and may increase the risk of fractures in postmenopausal women with early-stage breast cancer. The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss. Patients and Methods Patients receiving adjuvant letrozole were randomly assigned to receive either upfront or delayed-start zoledronic acid (4 mg intravenously every 6 months). The delayed group received zoledronic acid when lumbar spine (LS) or total hip (TH) T score decreased to less than −2.0 or when a nontraumatic fracture occurred. The primary end point of this study was to compare the change in LS BMD at month 12 between the groups. Secondary end points included change in TH BMD and changes in serum bone turnover markers at month 12. Results The upfront and delayed groups each included 301 patients. At month 12, LS BMD was 4.4% higher in the upfront group than in the delayed group (95% CI, 3.7% to 5.0%; P < .0001), and TH BMD was 3.3%...
300 citations
TL;DR: Cognitive function in women with early-stage breast cancer who received tamoxifen with those who received anastrozole therapy was compared in a cross-sectional study to validate and confirm the changes in cognitive function associated with hormone therapy for breast cancer.
Abstract: Objective: Hormones have been implicated as modulators of cognitive functioning. For instance, results of our previous work in women with breast cancer showed that cognitive impairment was more severe and involved more memory domains in those who received adjuvant tamoxifen therapy compared with women who received chemotherapy alone or no adjuvant therapy. Recently aromatase inhibitors such as anastrozole have been used in lieu of tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor-positive, early-stage breast cancer. Plasma estrogen levels are significantly lower in women who receive anastrozole compared with those who receive tamoxifen. We hypothesized, therefore, that anastrozole would have a more profound effect on cognitive function than tamoxifen, a mixed estrogen agonist/antagonist. Design: To test this hypothesis we compared cognitive function in women with early-stage breast cancer who received tamoxifen with those who received anastrozole therapy in a cross-sectional study. We evaluated cognitive function, depression, anxiety, and fatigue in 31 postmenopausal women with early-stage breast cancer who were between the ages of 21 and 65 years and treated with tamoxifen or anastrozole for a minimum of 3 months. Results: The results showed that women who received anastrozole had poorer verbal and visual learning and memory than women who received tamoxifen. Conclusions: Additional, prospective studies are needed to validate and confirm the changes in cognitive function associated with hormone therapy for breast cancer.
158 citations
TL;DR: Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy and early measures to prevent bone loss should be considered in this cohort of breast cancer survivors.
Abstract: Background: Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors. Objective: Our objective was to determine whether risedronate, 35 mg weekly, is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause. Design: The study was a randomized, double-blind, placebo-controlled clinical trial over 12 months. Setting and Participants: Participants included 87 newly postmenopausal women with status post chemotherapy, recruited from a breast cancer clinic in an academic medical center. Intervention: Participants were randomly assigned to receive risedronate 35 mg/wk or placebo. Main Outcome Measures: The primary outcomes were the 12-month changes in spine and hip bone mineral density. Secondary outcomes included changes in markers of bone resorption (urine N-telopeptide cross-linked collagen type I) and formation (osteocalcin, N-terminal propeptide of type I procollagen, and bone-specific alkaline phosphatase). Re...
56 citations
24 citations
15 citations
TL;DR: The use of bisphosphonates to minimize or prevent AI-induced bone loss in women with early-stage breast cancer is required and requires further study to more clearly define the most appropriate timing and length of therapy as well as the long-term efficacy and safety of these drugs.
12 citations
6 citations
TL;DR: registHER is a prospective observational study of approximately 1000 patients with newly diagnosed HER2+ MBC treated in community or academic settings and finds the influence of adjuvant HT on disease-free intervals (DFI) from time of diagnosis and MBC treat...
Abstract: 21007 Background: Approximately 50% of HER2+ breast cancers are HR+, however, the interaction between HER2 and HR is not completely understood. Patients with HR+/HER2+ or HR-/HER2+ tumors treated w...
2 citations